Two 12-amino acid peptides derived from human cathelicidin effectively killed carbapenem-resistant Acinetobacter baumannii in lab tests and significantly improved survival in infected mice.
MIC 2.5–20 µg/mL against CRABShort 12-amino acid peptides derived from human cathelicidin killed carbapenem-resistant A. baumannii clinical isolates at clinically relevant concentrations
What the researchers found
From 28 engineered dodecapeptides (12 amino acids) based on the antibacterial core of human cathelicidin, two leads emerged: d12 (linear) and d24 (hydrocarbon-stapled). Both killed carbapenem-resistant A. baumannii clinical isolates with MICs of 2.5–20 µg/mL by binding and penetrating bacterial membranes in a lipid A-dependent manner. In two mouse infection models — irradiation-assisted pulmonary infection and intra-abdominal sepsis — both peptides significantly reduced bacterial load and improved survival. The stapled d24 outperformed d12 in the sepsis model due to improved resistance to enzymatic degradation.
Why it matters
CRAB is classified by the WHO as a critical-priority pathogen with essentially no reliable treatment options. These short peptides derived from the human immune system offer a promising new therapeutic approach — they are potent, easy to synthesize, and the stapling technology addresses a major challenge in peptide drug development (enzymatic degradation). The in vivo efficacy data is particularly encouraging.
The numbers in context
28 dodecapeptides synthesized · MIC 2.5–20 µg/mL against CRAB isolates · 2 lead candidates (d12 linear, d24 stapled) · lipid A-dependent membrane penetration · improved mouse survival in 2 infection models
How the study worked
28 dodecapeptides were designed through site-directed mutation and all-hydrocarbon stapling of the KR12 antibacterial core of human cathelicidin LL-37. In vitro testing included MIC assays against CRAB clinical isolates, membrane binding and penetration studies, and biocompatibility assessments. In vivo efficacy was tested in two mouse models: irradiation-assisted local pulmonary infection and intra-abdominal sepsis with CRAB.
Who was studied
Carbapenem-resistant Acinetobacter baumannii clinical isolates tested in vitro and in mouse infection models (pulmonary and intra-abdominal sepsis)
What this study cannot tell us
Preclinical study — efficacy in humans has not been tested. The mouse infection models used irradiation-assisted immunosuppression, which may not reflect all clinical scenarios. Long-term toxicity and pharmacokinetic profiles were not detailed in the abstract. Cost comparison to existing therapies was not provided.
How to read the evidence
Strong preclinical study with both in vitro and in vivo data. The use of clinical isolates (not just lab strains) and two different mouse infection models strengthens the findings. However, human clinical data is still needed.
When this study was published
Published in 2025, this study represents cutting-edge antimicrobial peptide engineering using modern stapling technology to address one of the most urgent antibiotic resistance threats.
The bigger picture
The development of antimicrobial peptides from human cathelicidin represents a 'back to nature' approach to fighting superbugs. Hydrocarbon stapling — a technique that locks peptides into their active shape and protects them from degradation — is a significant advance that could make peptide antibiotics practical for clinical use. With the antibiotic pipeline dwindling, these engineered peptides could fill a critical gap.
Questions still open
- Could d12 and d24 be effective against other carbapenem-resistant Gram-negative pathogens beyond Acinetobacter?
- What are the manufacturing costs of stapled peptides at clinical scale, and how do they compare to conventional antibiotics?
- Would combination therapy with conventional antibiotics enhance the effectiveness of these peptide candidates?
Common questions
What is cathelicidin and why was it used as the starting point?
What is hydrocarbon stapling and why does it matter?
Read the original research
Dodecapeptides derived from human cathelicidin with potent activity against carbapenem-resistant Acinetobacter baumannii.
European journal of medicinal chemistry, 289, 117477
Citation
Jiang, Yiyi; Zhao, Gaomei; Gong, Yali; Chen, Yin; Li, Chenwenya; Han, Songling; Deng, Youcai; Zhao, Jinghong; Wang, Junping; Wang, Cheng. (2025). Dodecapeptides derived from human cathelicidin with potent activity against carbapenem-resistant Acinetobacter baumannii.. European journal of medicinal chemistry, 289, 117477. https://doi.org/10.1016/j.ejmech.2025.117477